Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02368886 · ClinicalTrials.gov registry record · Phase 2
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Academic and Community Cancer Research United.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT02368886 is a Phase 2 study that has completed, run by Academic and Community Cancer Research United. The registered enrollment target is 123 participants.
The verdict
NCT02368886, a Phase 2 study, has completed, sponsored by Academic and Community Cancer Research United.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well lower-dose compared to standard dose regorafenib works in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other places in the body and does not respond to treatment. Regorafenib may stop the growth of colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth and by blocking some of the enzymes needed for cell growth. It is not yet known whether lower-dose or standard dose regorafenib is more effective in treating patients with colorectal cancer. Clobetasol propionate is a steroid cream that is commonly used to treat a variety of skin conditions and may help prevent hand-foot skin reactions in patients receiving regorafenib.
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Regorafenib
- OTHER Pharmacological Study
- DRUG Clobetasol Propionate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2015-03-27 |
| Est. Completion | 2023-03-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02368886
The ClinicalTrials.gov registry entry for NCT02368886 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02368886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02368886 about?
NCT02368886 is a clinical study titled "Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer". This randomized phase II trial studies how well lower-dose compared to standard dose regorafenib works in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other places in the body and does not respond to treatment. Regorafenib may stop the gr...
What is the current status of trial NCT02368886?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2015-03-27. Estimated completion is 2023-03-02.
What interventions are being tested in trial NCT02368886?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Regorafenib (DRUG), Pharmacological Study (OTHER), Clobetasol Propionate (DRUG).
Who is sponsoring clinical trial NCT02368886?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.